Revision: Jan. 27, 2017, 9:27 a.m.
HB 443 - AS INTRODUCED
2017 SESSION
17-0269
05/09
HOUSE BILL 443
AN ACT prohibiting prescription drug manufacturers from offering copayment reimbursement.
SPONSORS: Rep. Kurk, Hills. 2; Rep. W. Marsh, Carr. 8
COMMITTEE: Commerce and Consumer Affairs
-----------------------------------------------------------------
This bill prohibits prescription drug manufacturers from offering to pay or reimburse an individual for his or her insurance copayment.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
17-0269
05/09
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Seventeen
AN ACT prohibiting prescription drug manufacturers from offering copayment reimbursement.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 New Subdivision; Copayment Reimbursement. Amend RSA 161-L by inserting after section 7 the following new subdivision:
Copayment Reimbursement
161-L:8 CoPayment Reimbursement Prohibited.
I. No prescription drug manufacturer doing business in New Hampshire shall establish a copayment reimbursement program or otherwise offer to pay, waive, or reimburse a patient for his or her insurance copayment.
II. This section shall apply to copayments required under any health insurance plan offered by a public or private entity.
III. Any person found in violation of this section shall be guilty of a violation.
2 Effective Date. This act shall take effect January 1, 2018.